New shot aims to stop breast cancer before it starts
NCT ID NCT07408856
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-phase trial tests a drug called CAN1012 in 24 people with pre-cancerous breast conditions (DCIS or LCIS). The drug is injected directly into the lesion to activate the immune system. The main goal is to check safety and ensure the treatment doesn't delay necessary surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Providence Portland Cancer Institute - Franz Clinic
Portland, Oregon, 97213, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Radiation may let breast cancer patients keep their nipple
- Could a sweat session rewrite breast cancer risk?
- Which workout wins for breast cancer recovery? a trial puts cardio vs conditioning to the test
- Could a Post-Workout protein shake help breast cancer survivors rebuild muscle?
- Hidden heart risk: routine cancer scans could reveal cardiovascular danger in breast cancer survivors